Active substance
Amcinonide
- US FDA 8
- Health Canada 1
- US price lines 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| AMCINONIDE | 0.1% | cream · topical | TARO PHARM INDS | Prescription | 31 May 2002 |
| AMCINONIDE | 0.1% | lotion · topical | SOLUBIOMIX | Prescription | 6 Nov 2002 |
| AMCINONIDE | 0.1% | ointment · topical | GENUS | Prescription | 19 Nov 2002 |
| CYCLOCORT | 0.025% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | cream · topical | ASTELLAS | Discontinued | 18 Oct 1979 |
| CYCLOCORT | 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ointment · topical | ASTELLAS | Discontinued | 13 Nov 1981 |
| CYCLOCORT | 0.1% | lotion · topical | ASTELLAS | Discontinued | 13 Jun 1988 |
| AMCINONIDE | 0.1% | ointment · topical | TARO PHARM INDS | Discontinued | 19 Mar 2003 |
| AMCINONIDE | 0.1% | cream · topical | GENUS LIFESCIENCES | Discontinued | 15 May 2003 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| TARO-AMCINONIDE | 02246714 | 0.1 % | CREAM · TOPICAL | TARO PHARMACEUTICALS INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | AMCINONIDE 0.1% CREAM | $4.90193 | per GM | 17 Jun 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.